Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of TBD11 in Healthy Adults
NCT07883226Phase 1Recruiting
- Sponsor
- Gates Medical Research Institute
- Start
- Oct 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Tat-beclin 1 D11 in Tuberculosis (TB) (4 cohorts), sponsored by Gates Medical Research Institute. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at Day 92, Number of Participants With Serious Adverse Events at Day 92 and 17 more. Started Oct 2026; status: recruiting.
02
Drugs
Tat-beclin 1 D11
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07883226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883226.